Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance

Annals of Internal Medicine

Volumn 126, Issue 8, 1997, Pages 608-614

  Yates, Charles R ^a,b   Krynetski, Eugene Y ^a,b   Loennechen, Thrina ^a,c   Fessing, Michael Y ^a,b   Tai, Hung Liang ^a,b   Pui, Ching Hon ^a,b   Relling, Mary V ^a,b   Evans, William E ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COMPLEMENTARY DNA; MERCAPTOPURINE; METHYLTRANSFERASE;

ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; CATALYSIS; DNA SEQUENCE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENE LOCUS; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0030934850     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-8-199704150-00003     Document Type: Article

References (26)

1. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, et al. Genetic polymorphism of thiopurine s-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics. 1996;6:279-90.
2. Leonard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic vanation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990;336:225-9.
3. Johnson PJ, McFarlane IG, Williams R. Azathiopnne for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995;333:958-63.
4. Pearson DC, May GR, Pick GH, Sutherland LR. Azathioporine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123: 132-42.
5. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioporine in Crohn's disease. Lancet. 1971;2:944-7.
6. Kerstens PJ, Stolk JN, Boerbooms AM, Lambooy LH, de Graaf R, De Abreu RA, et al. Purine enzymes in rheumatoid arthritis: possible association with response to azathioprine. A pilot study. Ann Rheum Dis. 1994;53:608-11.
7. Milanese C, La Mantia L, Salmaggi A, Eoli M. A double blind study of azathioporine efficacy in multiple sclerosis: final report. J Neurol. 1993;240: 295-8.
8. Cosi V, Lombardi M, Erbetta A, Piccolo G. Azathioporine as a single immunosuppressive drug in the treatment of myasthenia gravis. Acta Neurol (Napoli). 1993;15:123-31.
9. Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelo-suppression in thiopurine methyltransferase deficient heart transplant recipient [Letter]. Lancet 1993;341:436
10. Hollander AA, van Saase JL, Kootte AM, van Dorp WT, van Bockel HJ, van Es LA, et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet. 1995;345:610-4.
11. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr. 1991;119:985-9.
12. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient [Letter] Lancet. 1993;341:1151.
13. Lennard L, Gibson BE, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukemia. Arch Dis Child. 1993;69:577-9.
14. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-62.
15. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther. 1994;55:15-20.
16. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nudeotide concentrations. Clin Pharmacol Ther. 1987;41:18-25.
17. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet. 1990;336:529-32.
18. Grant DM. Molecular genetics of the n-acetyltransferases. Pharmacogenetics. 1993;3:45-50.
19. Krynetski EY, Schuetz JD, Galpin AJ. Pui CH, Rolling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine s-methyltransferase. Proc Natl Acad Sci USA. 1995;92:949-53.
20. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing M, Krynetskaia NF, et al. Thiopucine s-methyltransferase deficiency, two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996;58:694-702.
21. Szumlanski C, Otterness D, Her C, Lee O, Brandriff B, Kelsell D, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism DNA Cell Biol. 1996;15:17-30.
22. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta. 1978;85:323-33.
23. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987; 162:156-9.
24. Lee D, Szumlanski C, Houtman J, Honchel R, Rojas K, Overhauser J, et al. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metab Dispos. 1995;23:398-405.
25. Fodor SP, Rava RP, Huang XC, Pease AC, Holmes CP, Adams CL. Multiplexed biochemical assays with biological chips. Nature. 1993;364: 555-6.
26. Kreiner T. Rapid genetic sequence analysis using a DNA probe array system. American Laboratory. 1996;28:39-43.